Auspex Inks $25M More to Treat Hyperkinetic Movement Disorders
November 12, 2012
Share:
Auspex Pharmaceuticals has secured a $25 million Series D financing for Phase 3 development of its hyperkinetic movement disorder drug, SD-809. The drug compound is for the treatment of movement disorders including Huntington's disease, Tourette syndrome and tardive dyskinesia. Panorama Capital led the round, with previous backers Thomas McNerney & Partners, CMEA Capital, and Sloan Biotech Fund also participating.
